These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12727976)

  • 1. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome.
    Haqq AM; Stadler DD; Jackson RH; Rosenfeld RG; Purnell JQ; LaFranchi SH
    J Clin Endocrinol Metab; 2003 May; 88(5):2206-12. PubMed ID: 12727976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr; 1999 Feb; 134(2):215-21. PubMed ID: 9931532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical effects of growth hormone treatment in children with Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    Acta Paediatr Suppl; 1999 Dec; 88(433):112-4. PubMed ID: 10626559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.
    Carrel AL; Moerchen V; Myers SE; Bekx MT; Whitman BY; Allen DB
    J Pediatr; 2004 Dec; 145(6):744-9. PubMed ID: 15580194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome.
    Lafortuna CL; Minocci A; Capodaglio P; Gondoni LA; Sartorio A; Vismara L; Rizzo G; Grugni G
    J Clin Endocrinol Metab; 2014 May; 99(5):1816-24. PubMed ID: 24471571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
    Meinhardt U; Christiansen JS; Farholt S; Lämmer C; Ostergaard JR; Schmidt F; Kappelgaard AM; Eiholzer U
    Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
    Festen DA; van Toorenenbergen A; Duivenvoorden HJ; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1549-54. PubMed ID: 17264186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
    Coupaye M; Lorenzini F; Lloret-Linares C; Molinas C; Pinto G; Diene G; Mimoun E; Demeer G; Labrousse F; Jauregi J; Laurier V; Basdevant A; Polak M; Thuilleaux D; Tauber M; Poitou C
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E328-35. PubMed ID: 23284006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
    Lindgren AC; Lindberg A
    Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
    Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.